Akebia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)Documents filed as part of this Annual Report on Form 10-K.
(b)Consolidated Financial Statements
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Stockholders’ (Deficit) Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
(2)Schedules
Schedules have been omitted as all required information has been disclosed in the consolidated financial statements and related footnotes.
(3)Exhibits
The Exhibits listed below are filed as part of this Annual Report on Form 10-K.
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 2.1** | Agreement and Plan of Merger, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub, Inc., and Keryx Biopharmaceuticals, Inc. | 8-K | 001-36352 | 2.1 | June 28, 2018 |
| 2.2 | First Amendment to Agreement and Plan of Merger, dated as of October 1, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub, Inc. and Keryx Biopharmaceuticals, Inc. | 8-K | 001-36352 | 2.1 | October 1, 2018 |
| 3.1 | Ninth Amended and Restated Certificate of Incorporation | 8-K | 001-36352 | 3.1 | March 28, 2014 |
| 3.2 | Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Akebia Therapeutics, Inc. | 8-K | 001-36352 | 3.1 | June 9, 2020 |
| 3.3 | Second Amended and Restated Bylaws of Akebia Therapeutics, Inc. | 8-K | 001-36352 | 3.1 | April 28, 2023 |
| 4.1 | Form of Common Stock Certificate | S-1/A | 333-193969 | 4.1 | March 4, 2014 |
| 4.2 | Fourth Amended and Restated Investors’ Rights Agreement, dated March 5, 2014 | 10-K | 001-36352 | 4.4 | March 4, 2015 |
| 4.3# | Amendment No. 1 to Fourth Amended and Restated Investors’ Rights Agreement, dated June 28, 2017 | 10-K | 001-36352 | 4.5 | March 12, 2018 |
| 4.4# | Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated May 12, 2017 | 10-Q | 001-36352 | 4.1 | August 8, 2017 |
| 4.5! | Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated February 18, 2022 | 10-K | 001-36352 | 4.5 | March 1, 2022 |
| 4.6 | Description of Registrant’s Securities | 10-K | 001-36352 | 4.6 | February 25, 2021 |
| 4.7* | Form of Warrant | ||||
| 10.1† | Form of Director and Officer Indemnification Agreement | 10-K | 001-36352 | 10.1 | March 12, 2018 |
| 10.2 | Office Lease Agreement Between MA-Riverview/245 First Street, L.L.C. and Akebia Therapeutics, Inc., dated December 3, 2013 | S-1 | 333-193969 | 10.2 | February 14, 2014 |
| 10.3 | First Amendment to Office Lease Agreement Between Jamestown Premier 245 First, LLC and Akebia Therapeutics, Inc., dated December 15, 2014 | 10-K | 001-36352 | 10.3 | March 4, 2015 |
| 10.4 | Second Amendment to Office Lease Agreement Between Jamestown Premier 245 First, LLC and Akebia Therapeutics, Inc., dated November 23, 2015 | 10-K | 001-36352 | 10.4 | March 14, 2016 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.5 | Third Amendment to Office Lease Agreement Between Jamestown Premier 245 First, LLC and Akebia Therapeutics, Inc., dated July 25, 2016 | 10-Q | 001-36352 | 10.1 | November 9, 2016 |
| 10.6 | Fourth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc., dated May 1, 2017 | 10-K | 001-36352 | 10.6 | March 12, 2018 |
| 10.7 | Fifth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc. dated April 9, 2018 | 10-Q | 001-36352 | 10.1 | August 8, 2018 |
| 10.8 | Sixth Amendment to Office Lease Agreement Between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc. dated November 30, 2020 | 10-K | 001-36352 | 10.8 | February 25, 2021 |
| 10.9 | One Marina Park Drive Office Lease dated April 29, 2015, by and between Keryx Biopharmaceuticals, Inc. and Fallon Cornerstone One MPD LLC | 10-K | 000-30929 | 10.29 | March 1, 2017 |
| 10.10 | First Amendment to One Marina Park Drive Office Lease, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and CLPF One Marina Park Drive LLC (successor-in-interest to Fallon Cornerstone One MPD LLC) | 10-K | 001-36352 | 10.10 | March 1, 2022 |
| 10.11 | Assignment and Assumption Agreement, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc. | 10-K | 001-36352 | 10.11 | March 1, 2022 |
| 10.12 | Sublease, dated as of September 9, 2019, by and between Keryx Biopharmaceuticals, Inc. and Foundation Medicine, Inc. | 10-Q | 001-36352 | 10.1 | November 12, 2019 |
| 10.13† | Amended and Restated 2008 Equity Incentive Plan | S-1 | 333-193969 | 10.5 | February 14, 2014 |
| 10.14† | Amendment No. 1 to Amended and Restated 2008 Equity Incentive Plan | S-1 | 333-193969 | 10.6 | February 14, 2014 |
| 10.15† | Executive Employment Agreement with John P. Butler, dated September 16, 2013 | S-1 | 333-193969 | 10.7 | February 14, 2014 |
| 10.16† | Offer Letter to David Spellman, dated as of June 13, 2020 | 10-Q | 001-36352 | 10.1 | August 10, 2020 |
| 10.17† | Form of Non-Statutory Stock Option Agreement for Officers | S-1/A | 333-193969 | 10.24 | March 4, 2014 |
| 10.18† | Form of Non-Statutory Stock Option Agreement for Non-Employee Directors | S-1/A | 333-193969 | 10.25 | March 4, 2014 |
| 10.19† | Amended and Restated Non-Employee Director Compensation Program, effective April 27, 2023 | 10-Q | 001-36352 | 10.1 | May 8, 2023 |
| 10.20† | Second Amended and Restated Non-Employee Director Compensation Program, effective June 6, 2023 | 10-Q | 001-36352 | 10.8 | August 28, 2023 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.21†* · Third Amended and Restated Non-Employee Director Compensation Program, effective January 1, 2024 | |||||
| 10.22† | Form of Executive Severance Agreement for Officers | S-1/A | 333-193969 | 10.27 | March 4, 2014 |
| 10.23† | 2014 Incentive Plan | S-1 | 333-193969 | 10.29 | March 4, 2014 |
| 10.24† | Amendment No. 1 to the Akebia Therapeutics, Inc. 2014 Incentive Plan | S-8 | 333-229366 | 4.4 | January 25, 2019 |
| 10.25† | Amended and Restated 2014 Employee Stock Purchase Plan | DEF 14A | 001-36352 | Appendix A | April 26, 2019 |
| 10.26† | Amended and Restated Cash Incentive Plan, effective January 19, 2022 | 10-K | 001-36352 | 10.28 | March 1, 2022 |
| 10.27† | Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan | 10-K | 001-36352 | 10.18 | March 12, 2018 |
| 10.28† | Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan | 10-K | 001-36352 | 10.29 | March 26, 2019 |
| 10.29† | Form of Officer Inducement Award Non-Statutory Stock Option Agreement | S-8 | 333-222728 | 4.4 | January 26, 2018 |
| 10.30† | Form of Inducement Award Non-Statutory Stock Option Agreement for Non-Officers | S-8 | 333-222728 | 4.5 | January 26, 2018 |
| 10.31† | Form of Officer Performance-Based Stock Option Award, under the Company's 2014 Incentive Plan, as amended | 10-Q | 001-36352 | 10.1 | November 4, 2021 |
| 10.32† | Form of Officer Performance-Based Stock Restricted Stock Unit Award, under the Company's 2014 Incentive Plan, as amended | 10-Q | 001-36352 | 10.2 | November 4, 2021 |
| 10.33† | Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan (Retention Awards) | 10-Q | 001-36352 | 10.6 | August 4, 2022 |
| 10.34† | Form of Officer Non-Statutory Stock Option Agreement under 2014 Incentive Plan (Retention Awards) | 10-Q | 001-36352 | 10.7 | August 4, 2022 |
| 10.35†! | Form of Officer Cash Bonus Letter Agreement | 10-Q | 001-36352 | 10.3 | November 4, 2021 |
| 10.36† | Form of Officer Stock Appreciation Rights Award Agreement under 2014 Incentive Plan | 10-Q | 001-36352 | 10.3 | May 8, 2023 |
| 10.37† | Akebia Therapeutics, Inc. 2023 Stock Incentive Plan | S-8 | 333-272453 | 99.1 | June 6, 2023 |
| 10.38† | Form of Non-Employee Director Stock Option Agreement under 2023 Stock Incentive Plan | 10-Q | 001-36352 | 10.10 | August 28, 2023 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.39† | Form of Non-Employee Director Restricted Stock Unit Agreement under 2023 Stock Incentive Plan | 10-Q | 001-36352 | 10.12 | August 28, 2023 |
| 10.40† | Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan | 10-Q | 001-36352 | 10.11 | August 28, 2023 |
| 10.41† | Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan | 10-Q | 001-36352 | 10.13 | August 28, 2023 |
| 10.42† | Form of Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan | 10-Q | 001-36352 | 10.14 | August 28, 2023 |
| 10.43*† | Form of Officer Executive Severance Agreement (Reflecting Clawback Policy) | ||||
| 10.44*† | Form of Officer Cash Bonus Agreement (Reflecting Clawback Policy) | ||||
| 10.45*† | Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) | ||||
| 10.46*† | Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) | ||||
| 10.47*† | Form of Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) | ||||
| 10.48† | Keryx Biopharmaceuticals, Inc. 1999 Stock Option Plan | 10-Q | 001-30929 | 10.2 | March 21, 2003 |
| 10.49† | Keryx Biopharmaceuticals, Inc. 2004 Long-Term Incentive Plan | DEF 14A | 000-30929 | Annex C | April 29, 2004 |
| 10.50† | Amendment to the Keryx Biopharmaceuticals, Inc. 2004 Long-Term Incentive Plan dated April 11, 2006 | 10-Q | 000-30929 | 10.1 | August 9, 2006 |
| 10.51† | Keryx Biopharmaceuticals, Inc. 2007 Incentive Plan | DEF 14A | 000-30929 | Annex D | April 30, 2007 |
| 10.52† | Keryx Biopharmaceuticals, Inc. Amended and Restated 2013 Incentive Plan | 8-K | 000-30929 | 10.1 | May 27, 2016 |
| 10.53† | Keryx Biopharmaceuticals, Inc. 2018 Equity Incentive Plan | S-8 | 333-226005 | 99.1 | June 29, 2018 |
| 10.54† | Form of Indemnification Agreement between Keryx Biopharmaceuticals, Inc. and its Directors and Officers | 10-Q | 000-30929 | 10.1 | November 9, 2016 |
| 10.55† | Form of Employee Agreement (Confidentiality, Non-Competition, Non-Solicitation and Development Agreement) applicable to Officers | 10-K | 001-36352 | 10.56 | March 26, 2019 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.56† | Keryx Biopharmaceuticals, Inc. Fourth Amended and Restated Directors Equity Compensation Plan | 8-K | 000-30929 | 10.2 | May 27, 2016 |
| 10.57† | Keryx Biopharmaceuticals, Inc. Third Amended and Restated Directors Equity Compensation Plan | 10-Q | 000-30929 | 10.1 | August 7, 2014 |
| 10.58† | Keryx Biopharmaceuticals, Inc. Director Non-Statutory Stock Option Award Terms and Conditions under the Third Amended and Restated Directors Equity Compensation Plan | 10-K | 001-36352 | 10.59 | March 26, 2019 |
| 10.59† | Form of Officer Retention Letter Agreement | 10-Q | 001-36352 | 10.6 | May 9, 2022 |
| 10.60†! | Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas | 10-Q | 001-36352 | 10.7 | May 9, 2022 |
| 10.61†! | Form of Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas | 10-Q | 001-36352 | 10.2 | November 3, 2022 |
| 10.62†! | Form of May 2023 Amendment to Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas | 10-Q | 001-36352 | 10.4 | August 28, 2023 |
| 10.63†! | July 2023 Amendment to Retention and Separation Agreement for Michel Dahan | 10-Q | 001-36352 | 10.5 | August 28, 2023 |
| 10.64†! | July 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas | 10-Q | 001-36352 | 10.6 | August 28, 2023 |
| 10.65†! | October 2023 Amendment to Retention and Separation Agreement for Nicole R. Hadas | 10-Q | 001-36352 | 10.3 | November 8, 2023 |
| 10.66*†! | February 2024 Amendment to Retention and Separation Agreement for Nicole R. Hadas | ||||
| 10.67*†! | February 2024 Amendment to Retention and Separation Agreement for Michel Dahan | ||||
| 10.68† | Retention Agreement with David Spellman, dated June 22, 2022 | 10-Q | 001-36352 | 10.5 | August 4, 2022 |
| 10.69† | Separation Agreement with David Spellman, dated June 9, 2023 and Amendment to Separation Agreement dated July 6, 2023 | 10-Q | 001-36352 | 10.7 | August 28, 2023 |
| 10.70! | Collaboration Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated December 11, 2015 | 10-K | 001-36352 | 10.49 | March 1, 2022 |
| 10.71# | Letter Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated September 26, 2017 | 10-Q | 001-36352 | 10.1 | November 8, 2017 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.72! | Amendment No. 1 to Collaboration Agreement, dated December 2, 2022, by and between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation | 10-K | 001-36352 | 10.53 | March 10, 2022 |
| 10.73! | Termination and Settlement Agreement, dated June 30, 2022, by and between the Company and Otsuka Pharmaceutical Co. Ltd. | 10-Q | 001-36352 | 10.8 | August 4, 2022 |
| 10.74! | Packaging Validation Transfer Agreement, dated April 20, 2023, by and between the Company and Otsuka Pharmaceutical Co. Ltd. | 10-Q | 001-36352 | 10.3 | August 28, 2023 |
| 10.75! | Second Amended and Restated License Agreement, dated February 18, 2022, by and between Akebia Therapeutics, Inc. and Vifor (International) Ltd. | 10-K | 001-36352 | 10.54 | March 1, 2022 |
| 10.76 | Open Market Sale AgreementSM, dated April 7, 2022, by and between Akebia Therapeutics, Inc. and Jefferies LLC | 8-K | 001-36352 | 1.1 | April 7, 2022 |
| 10.77! | Second Amended and Restated License Agreement dated April 17, 2019, by and between Akebia Therapeutics, Inc. and Panion & BF Biotech, Inc. | 10-Q | 001-36352 | 10.1 | August 8, 2019 |
| 10.78# | Amended and Restated Sub-License Agreement, dated June 8, 2009, as amended by the First Amendment thereto, dated June 12, 2013, by and between Keryx Biopharmaceuticals, Inc., Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd | 10-Q | 000-30929 | 10.1 | November 7, 2017 |
| 10.79! | Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates, dated September 27, 2016, and related Product Agreement dated September 27, 2016, and related Product Agreement dated October 12, 2016 | 10-K | 001-36352 | 10.58 | March 1, 2022 |
| 10.80# | Product Agreement, dated August 29, 2017, by and between Keryx Biopharmaceuticals, Inc. and Patheon Inc. (an affiliate of Patheon Manufacturing Services LLC) related to the Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates dated November 12, 2016 | 10-Q | 000-30929 | 10.2 | November 7, 2017 |
| 10.81# | Master Manufacturing Services and Supply Agreement, dated December 20, 2017, by and between Keryx Biopharmaceuticals, Inc. and Siegfried Evionnaz SA | 10-K | 000-30929 | 10.13 | February 21, 2018 |
| 10.82 | Amendment No. 1 to Master Manufacturing Services and Supply Agreement, dated as of December 21, 2020, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc. | 10-K | 001-36352 | 10.57 | February 25, 2021 |
| 10.83 | Amendment No. 2 to Master Manufacturing Services and Supply Agreement, dated as of January 29, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc. | 10-K | 001-36352 | 10.58 | February 25, 2021 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.84! | Amendment No. 3 to Master Manufacturing Services and Supply Agreement, dated as of February 11, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc. | 10-K | 001-36352 | 10.59 | February 25, 2021 |
| 10.85 | Amendment No. 4 to Master Manufacturing Services and Supply Agreement, dated as of December 17, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc. | 10-K | 001-36352 | 10.64 | March 1, 2022 |
| 10.86! | Amendment No. 5 to Master Manufacturing Services and Supply Agreement, dated February 28, 2023, by and between Keryx Biopharmaceuticals, Inc. and Siegfried Evionnaz SA | 10-Q | 001-36352 | 10.2 | May 8, 2023 |
| 10.87# | Exclusive Distribution Agreement between Keryx Biopharmaceuticals, Inc. and Cardinal Health 105, Inc., dated October 16, 2014 and First Amendment to Exclusive Distribution Agreement between Keryx Biopharmaceuticals, Inc. and Cardinal Health 105, Inc., dated April 14, 2015 | 10-K | 001-36352 | 10.60 | March 26, 2019 |
| 10.88! | Termination and Settlement Agreement, dated December 22, 2022, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc. | 10-K | 001-36352 | 10.70 | March 10, 2023 |
| 10.89! | Loan Agreement, dated November 11, 2019, by and among the Company, Keryx Biopharmaceuticals, Inc., Biopharma Credit plc and Biopharma Credit Investments V (Master) LP | 10-K | 001-36352 | 10.62 | March 12, 2020 |
| 10.90! | First Amendment and Waiver, dated February 18, 2022, by and among the Company, Biopharma Credit plc, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP | 10-K | 001-36352 | 10.69 | March 1, 2022 |
| 10.91! | Second Amendment and Waiver, dated July 15, 2022, by and among the Company, Biopharma Credit plc, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP | 10-Q | 001-36352 | 10.9 | August 4, 2022 |
| 10.92! | Third Amendment to Loan Agreement, dated as of June 30, 2023, by and among the Company, Biopharma Credit plc, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP | 10-Q | 001-36352 | 10.2 | August 28, 2023 |
| 10.93*! | Fourth Amendment to Loan Agreement dated as of October 31, 2023, by and among the Company, BioPharma Credit PLC, BPCR Limted Partnership, and BioPharma Credit Investments V (Master) LP | ||||
| 10.94! | Guaranty and Security Agreement, dated November 25, 2019, by and between the Company, Keryx Biopharmaceuticals, Inc. and Biopharma Credit plc | 10-K | 001-36352 | 10.63 | March 12, 2022 |
| 10.95! | Supply Agreement, dated as of March 11, 2020, by and between Akebia Therapeutics, Inc. and Patheon, Inc. | 10-Q | 001-36352 | 10.1 | May 5, 2020 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 10.96! | Supply Agreement, dated as of April 2, 2020, by and between Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited | 10-Q | 001-36352 | 10.2 | August 10, 2020 |
| 10.97! | Amendment No. 1 to the Supply Agreement, dated as of April 15, 2021, by and between Akebia Therapeutics, Inc, and STA Pharmaceutical Hong Kong Limited | 10-Q | 001-36352 | 10.1 | August 5, 2021 |
| 10.98! | Supply Agreement, dated February 10, 2021, by and between the Company and STA Pharmaceutical Hong Kong Limited | 10-Q | 001-36352 | 10.4 | May 10, 2021 |
| 10.99! | Royalty Interest Acquisition Agreement, dated February 25, 2021, by and between the Company and HealthCare Royalty Partners IV, L.P. | 10-Q | 001-36352 | 10.5 | May 10, 2021 |
| 10.100! | License Agreement, dated December 22, 2022, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS | 10-K | 001-36352 | 10.81 | March 10, 2023 |
| 10.101! | License Agreement, dated May 24, 2023, by and between the Company and MEDICE Arzneimittel Pütter GmbH & Co. KG | 10-Q | 001-36352 | 10.1 | August 28, 2023 |
| 10.102*! | Agreement for the Provision of a Loan Facility dated January 29, 2024 between the Company and Kreos Capital VII (UK) Limited | ||||
| 10.103* | Warrant Agreement dated January 29, 2024 by and between the Company and Kreos Capital VII Aggregator SCSp | ||||
| 21.1 | List of Subsidiaries | 10-K | 001-36352 | 21.1 | February 25, 2021 |
| 23.1* | Consent of Ernst & Young LLP | ||||
| 31.1* | Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended | ||||
| 31.2* | Certification of Principal Financial Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended | ||||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. 1350 | ||||
| 97.1†* | Akebia Therapeutics, Inc. Dodd-Frank Compensation Recovery Policy | ||||
| 101.INS* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document) | ||||
| Incorporated by Reference | |||||
| ExhibitNumber | Description of Exhibit | Schedule/ Form | File No. | Exhibit | Filed Date/ Period End Date |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB* | Inline XBRL Taxonomy Extension Labels Linkbase Document | ||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
- Filed, or submitted electronically, herewith
† Indicates management contract or compensatory plan
Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment
! Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K
** The schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of such schedules to the Securities and Exchange Commission upon request by the Commission
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.